MARKET

MDWD

MDWD

Mediwound
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.800
-0.010
-0.55%
Closed 15:57 05/19 EDT
OPEN
1.770
PREV CLOSE
1.810
HIGH
1.815
LOW
1.731
VOLUME
21.94K
TURNOVER
--
52 WEEK HIGH
6.22
52 WEEK LOW
1.250
MARKET CAP
58.52M
P/E (TTM)
-3.6174
1D
5D
1M
3M
1Y
5Y
Is MediWound (NASDAQ:MDWD) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 15h ago
Wells Fargo Adjusts MediWound's Price Target to $8 From $7, Keeps Overweight Rating
MT Newswires · 1d ago
Sector Update: Health Care Stocks Rising Ahead of Tuesday Close
MT Newswires · 2d ago
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 1.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 2d ago
MediWound: Q1 Earnings Insights
  MediWound (NASDAQ:MDWD) reported its Q1 earnings results on Tuesday, May 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 2d ago
MediWound picks industry veteran for CEO role
MediWound (NASDAQ:MDWD) appointed Ofer Gonen as CEO, effective June 30, 2022, succeeding Sharon Malka, who will join the company board. Ofer Gonen has been a board member in MediWound and the CEO of Clal Biotechnology Industries, MediWound's
Seekingalpha · 2d ago
BRIEF-Mediwound Reports First Quarter 2022 Financial Results
reuters.com · 2d ago
MediWound GAAP EPS of -$0.12 misses by $0.01, revenue of $4.4M beats by $0.11M
MediWound press release (NASDAQ:MDWD): Q1 GAAP EPS of -$0.12 misses by $0.01. Revenue of $4.4M (-24.8% Y/Y) beats by $0.11M. Shares -3.17% PM.
Seekingalpha · 2d ago
More
No Data
Learn about the latest financial forecast of MDWD. Analyze the recent business situations of Mediwound through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MDWD stock price target is 6.25 with a high estimate of 8.00 and a low estimate of 3.000.
High8.00
Average6.25
Low3.000
Current 1.800
EPS
Actual
Estimate
-0.12-0.09-0.06-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 41
Institutional Holdings: 3.93M
% Owned: 12.09%
Shares Outstanding: 32.51M
TypeInstitutionsShares
Increased
8
313.31K
New
5
108.28K
Decreased
9
274.91K
Sold Out
2
28.01K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.15%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Chairman/Independent Director
Stephen Wills
Chief Executive Officer
Sharon Malka
Chief Financial Officer
Boaz Gur-Lavie
Executive Vice President/General Counsel/Secretary
Yaron Meyer
Chief Technology Officer
Lior Rosenberg
Other
Ety Klinger
Director
David Fox
Director
Ofer Gonen
Director
Samuel Moed
Director
Assaf Segal
Independent Director
Vickie Driver
Independent Director
Sharon Kochan
Independent Director
Nissim Mashiach
No Data
No Data
About MDWD
MediWound Ltd. is a Israel-based biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Webull offers kinds of Mediwound Ltd stock information, including NASDAQ:MDWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDWD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDWD stock methods without spending real money on the virtual paper trading platform.